All In Biotech

Free tool

FAERS Monitor: Zenbexus

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 221075 or its brand name (Zenbexus, Iberdomide Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

149

Serious

143

96% of reports

Hospitalization

90

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • febrile neutropenia22
  • neutropenia19
  • pneumonia13
  • thrombocytopenia12
  • covid-1911
  • plasma cell myeloma10
  • infection8
  • fatigue7
  • mixed liver injury7
  • rash7
  • anaemia6
  • phlebitis6
  • sepsis6
  • bone marrow failure5
  • covid-19 pneumonia5

Reports by year received

View as table
YearReports
20204
20216
202220
202364
202411
202521
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,010 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mixed liver injurySignal7329.2159.61,969
phlebitisSignal6165.675.6823
covid-19 pneumoniaSignal559.825.3233
febrile neutropeniaSignal2246.831.8944
plasma cell myelomaSignal1036.219.9308
bone marrow failureSignal534.714.7132
neutropeniaSignal1919.713.0321
thrombocytopeniaSignal1215.18.8146
covid-19Signal118.95.070
infectionSignal87.84.041
sepsisSignal67.63.528
pneumoniaSignal135.73.446
anaemiaSignal64.42.013
rash72.31.14
fatigue71.30.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.